Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 2;10(11):e005503. doi: 10.1136/jitc-2022-005503

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

The landscape of mutational signatures, expression and prognosis of APOBEC3B in pan-cancer. (A) The mutational signatures across pan-cancer from The Cancer Genome Atlas (TCGA) database. Cancer types were arranged as columns, and mutation signatures were displayed as rows. ‘Unknown’ represented mutation signatures that were unknown, unverified, or failed to be verified. MMR: mismatch repair. (B) Expression levels of APOBEC family members in normal and tumor tissues of human esophageal squamous carcinoma and colon cancer from Gene Expression Omnibus (GEO) database were analyzed. Data from GEO database have performed background correction and normalization by using the Robust Multiarray Average (RMA) algorithm in Bioconductor of R package, *p<0.05, **p<0.01, ***p<0.001. (C) Kaplan-Meier overall survival curve showed the relationship between APOBEC3B expression and pan-cancer patients’ overall survival (n=4636 for APOBEC3B-low and n=5905 for APOBEC3B-high based on receiver operating characteristic (ROC) curve analysis).